Literature DB >> 21327753

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.

Jon P Fryzek1, William J Martone, Jessie R Groothuis.   

Abstract

INTRODUCTION: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants and young children and the leading cause of hospitalization in infants aged <1 year.
METHODS: We examined trends in RSV hospitalization (RSVH) among infants from 1998 to 2006, using the United States (US) National Hospital Discharge Survey (NHDS) database. RSVH was defined by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes 079.6 (RSV), 466.11 (acute bronchiolitis due to RSV), and 480.1 (pneumonia due to RSV). Age at the time of hospitalization was determined using NHDS birth records; RSVH rates were analyzed for infants grouped into three age cohorts (<3 months, 3 to 6 months, and >6 to <24 months). Trends in hospitalization rates were evaluated using linear regression. Relative rates (RR) and 95% confidence intervals (CI) were computed to compare average RSVH rates for infants across age-specific groups. The annual proportion of RSVH by age group was also calculated.
RESULTS: Approximately 1.1 million (90,000-147,000 per year) RSVHs in predominantly term children aged <24 months were analyzed. Compared with children aged >6 to <24 months, rates for RSVH were significantly higher among infants aged <3 months (RR, 7.38; 95% CI, 7.35-7.41) and infants aged 3 to 6 months (RR, 5.28; 95% CI, 5.26-5.29). The proportion of RSVH in the first year of life was lowest among infants aged <1 month (9%). [corrected] The greatest proportion of RSVH was observed in children aged 3 to 6 months (14%-23% RSVH per year; chi-square P<0.0001). When the definition of RSVH was expanded to include unspecified hospitalizations for acute bronchiolitis, similar results were observed.
CONCLUSION: RRs were highest among the <3- month and 3- to 6-month age groups. The highest proportion of RSVH was among the 3- to 6-month age group. Analysis of the impact of RSV season, clinical practices, and other factors on these trends is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327753     DOI: 10.1007/s12325-010-0106-6

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  15 in total

1.  Fulminant Clostridium difficile infection: An association with prior appendectomy?

Authors:  Jesse Clanton; Michael Subichin; Katherine Drolshagen; Timothy Daley; Michael S Firstenberg
Journal:  World J Gastrointest Surg       Date:  2013-08-27

Review 2.  Host and Viral Determinants of Respiratory Syncytial Virus-induced Airway Mucus.

Authors:  Matthew T Stier; R Stokes Peebles
Journal:  Ann Am Thorac Soc       Date:  2018-11

3.  Reduced inflammation and altered innate response in neonates during paramyxoviral infection.

Authors:  Somashubhra Bhattacharya; Brandon T Beal; Ann M Janowski; Laurie P Shornick
Journal:  Virol J       Date:  2011-12-20       Impact factor: 4.099

4.  Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.

Authors:  Chyong-Hsin Hsu; Chia-Ying Lin; Hsin Chi; Jui-Hsing Chang; Han-Yang Hung; Hsin-An Kao; Chun-Chih Peng; Wai-Tim Jim
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

Review 5.  Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.

Authors:  Doris Makari; Paul A Checchia; John Devincenzo
Journal:  Hum Vaccin Immunother       Date:  2013-12-06       Impact factor: 3.452

Review 6.  Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries.

Authors:  Louis Bont; Paul A Checchia; Brigitte Fauroux; Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-08-01

7.  A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.

Authors:  Hsin Chi; Chyong-Hsin Hsu; Jui-Hsing Chang; Nan-Chang Chiu; Han-Yang Hung; Hsin-An Kao; Li-Chuan Weng; Fu-Yuan Huang; Yu-Ying Chiu; Luan-Yin Chang; Li-Min Huang
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

8.  Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Authors:  Christopher S Ambrose; Evan J Anderson; Eric A F Simões; Xionghua Wu; Hanaa Elhefni; C Lucy Park; Frangiscos Sifakis; Jessie R Groothuis
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

9.  Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.

Authors:  Michela Silvestri; Francesca Marando; Anna Maria Costanzo; Umberto di Luzio Paparatti; Giovanni A Rossi
Journal:  Ital J Pediatr       Date:  2016-04-26       Impact factor: 2.638

10.  Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

Authors:  John P DeVincenzo; Christopher S Ambrose; Doris Makari; Leonard B Weiner
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.